Figures & data
Figure 1 Lower HDAC6 expression was exhibited in MLNs than in the corresponding esophageal squamous cell cancer PT.
Notes: (A) Representative immunohistochemical staining of a patient whose HDAC6 expression was higher in the PT (left) than in MLNs (right). (B) Representative immunohistochemical staining of a patient whose HDAC6 expression was lower in the PT (left) than in MLNs (right) (magnification ×400). (C) Paired comparison of HDAC6 staining scores of PTs and MLNs. ***P<0.001, Wilcoxon matched-pair signed-rank test.
Abbreviations: HDAC6, histone deacetylase 6; MLN, metastatic lymph node; PT, primary tumor.
Table 1 HDAC6 protein expression in PTs and MLNs and their correlations with clinicopathological features of patients with esophageal squamous cell cancer
Figure 2 ROC curves used HDAC6 expression scores of (A) MLNs and (B) PTs to select cutoff values. The optimal cutoff value was determined by maximizing an AUC to discriminate between survival and 18-month cancer-specific death.
Abbreviations: AUC, area under the ROC curve; HDAC6, histone deacetylase 6; MLN, metastatic lymph node; PT, primary tumor; ROC, receiver operating characteristics.
Figure 3 Kaplan–Meier survival analyses for surgically resected T3N1–3M0 esophageal squamous cell carcinomas revealed that HDAC6 expression levels in MLNs (A, B), but not in PTs (C, D), were prognostic factors.
Abbreviations: HDAC6, histone deacetylase 6; MLN, metastatic lymph node; PT, primary tumor.
Table 2 Univariate and multivariate analyses of prognostic variables in patients with esophageal squamous cell cancer
Figure 4 Subgroup analyses for surgically resected T3N1–3M0 esophageal squamous cell carcinomas according to different N status.
Note: The prognostic significance of HDAC6 expression in MLNs was found only for N1 patients (A, B), not N2 (C, D), or N3 patients (E, F).
Abbreviations: HDAC6, histone deacetylase 6; MLN, metastatic lymph node.
